CytomX Therapeutics (CTMX) Operating Leases (2019 - 2025)

CytomX Therapeutics has reported Operating Leases for 7 years, with the latest figure at $1.4 million in Q2 2025.

• For the quarter ending Q2 2025, Operating Leases fell 79.06% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2025 stood at $1.4 million (down 79.06% YoY), and the FY2024 full-year result was $4.2 million, down 54.82% from the prior year.
• Operating Leases for Q2 2025 stood at $1.4 million, down from $2.9 million in the prior quarter.
• The five-year high for Operating Leases was $20.8 million in Q1 2021, with the low at $1.4 million in Q2 2025.
• Historically, Operating Leases has averaged $11.9 million across 5 years, with a median of $12.3 million in 2023.
• Annual changes were most pronounced in 2021 — Operating Leases decreased 13.68% — and 2025, when it plunged 79.06%.
• CytomX Therapeutics' Operating Leases stood at $18.1 million in 2021, then retreated by 22.6% to $14.0 million in 2022, then sank by 32.84% to $9.4 million in 2023, then plunged by 54.82% to $4.2 million in 2024, then plunged by 65.99% to $1.4 million in 2025.
• The last three Operating Leases figures came in at $1.4 million (Q2 2025), $2.9 million (Q1 2025), and $4.2 million (Q4 2024), per Business Quant data.